Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Orelabrutinib Wins Approval in China for First-Line CLL and SLL

April 25th 2025

China’s NMPA has approved orelabrutinib for the first-line treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma.

Meta Analysis Shows Efficacy Trend Favoring Zanubrutinib in High-Risk R/R CLL

April 24th 2025

A network meta analysis compared the efficacy of BTK inhibitors in patients with high-risk R/R chronic lymphocytic leukemia.

Dr Shadman on the Framework of a Meta Analysis of BTK Inhibitors in R/R CLL

April 21st 2025

Mazyar Shadman, MD, MPH, discusses the rationale and methodological framework of a network meta-analysis aimed at evaluating the comparative efficacy of BTK inhibitors in R/R CLL.

The OncFive: Top Oncology Articles for the Week of 4/13

April 19th 2025

Nogapendekin alfa inbakicept sBLA in NMIBC has been filed to FDA for review, a bexmarilimab combination elicits responses in MDS, and more from OncLive.

Dr Hernandez-Ilizaliturri on Studying Immunologic Changes With Venetoclax in CLL

April 18th 2025

Francisco J. Hernandez-Ilizaliturri, MD, discusses the rationale behind assessing immunologic changes seen with venetoclax treatment in patients with CLL.

Dr Alencar on the Ongoing Development of NX-5948 in CLL and B-Cell Malignancies

April 18th 2025

Alvaro Alencar, MD, discusses research needed to clarify the optimal dosing, role, and sequencing of NX-5948 in CLL and other B-cell malignancies.

MRD-Guided Zanubrutinib/Venetoclax/Obinutuzumab Triplet Induces Deep Remissions in R/R CLL

April 16th 2025

Zanubrutinib plus venetoclax and obinutuzumab was well tolerated—aside from COVID-19–related toxicities—in patients with relapsed/refractory CLL.

Dr Opat on the Unique Mechanism of Action of Sonrotoclax in R/R CLL

April 16th 2025

Stephen Opat, MBBS, explains the unique mechanism of action of sonrotoclax and how it differs from venetoclax for the treatment of patients with relapsed/refractory CLL or SLL.

Dr Ghia on the Role of Fixed-Duration Ibrutinib Plus Venetoclax in CLL and Beyond

April 14th 2025

Paolo Ghia, MD, PhD, discusses ongoing and future directions for the investigation of fixed-duration ibrutinib/venetoclax in CLL.

Five Under 5: Top Oncology Videos for the Week of 4/6

April 13th 2025

The top 5 OncLive videos of the week cover insights in myelofibrosis, chronic lymphocytic leukemia, colorectal cancer, breast cancer, and ovarian cancer.

Dr Cortese on Methods for Evaluating immunologic Changes With Venetoclax in CLL

April 11th 2025

Matthew Cortese, MD, MPH, discusses the methods used to produce a comprehensive map of immune changes that occur with venetoclax treatment in CLL.

Dr Ghia on Fixed-Duration Ibrutinib Plus Venetoclax in First-Line CLL

April 7th 2025

Paolo Ghia, MD, PhD, discusses long-term data for fixed-duration ibrutinib plus venetoclax in chronic lymphocytic leukemia.

Acalabrutinib Produces High ORR in Chinese Patients With R/R CLL

April 4th 2025

Acalabrutinib was effective in a population of patients from China with relapsed/refractory CLL.

Dr Coombs on the Need for Consensus to Define High-Risk CLL

March 19th 2025

Catherine C. Coombs, MD, discusses the need to establish a standardized definition of high-risk CLL.

Dr Alencar on Unmet Needs Associated With BTK Inhibitor Resistance in CLL

March 17th 2025

Alvaro Alencar, MD, discusses current unmet needs following the development of covalent BTK inhibitor resistance in CLL.

Acalabrutinib Plus Venetoclax and Obinutuzumab Displays High Level of Activity in First-Line High-Risk CLL

March 13th 2025

Acalabrutinib with venetoclax and obinutuzumab was effective and well tolerated in treatment-naive CLL harboring a TP53 aberration.

HCP Survey Outlines Challenges, Strategies for Venetoclax Initiation in CLL in the Community Setting

March 12th 2025

John M. Burke, MD, discusses identified challenges in the initiation of venetoclax in patients with CLL within a community-based setting.

Dr Cortese on the Benefits of a Multiomic Evaluation of Immunologic Changes in CLL After Venetoclax

March 10th 2025

Matthew Cortese, MD, MPH, discusses the benefit of analyzing multiple biological layers when identifying immunologic changes in CLL after venetoclax.

Bridging Data and Expert Insights: Paving the Way for Improved CLL Outcomes

March 10th 2025

On February 13, 2025, a select group of experts in chronic lymphocytic leukemia (CLL) participated in a virtual workshop to discuss the evolving treatment landscape of CLL and discussed subjects ranging from treatment of newly diagnosed patients to therapies for those relapsed/refractory (R/R) disease. Moderated by Alexey V. Danilov, MD, PhD, the discussion covered insights into emerging treatment approaches, novel therapeutic strategies, and sequencing of available therapies to optimize patient outcomes. This article was supported in part by Eli Lilly. Content independently developed and published by OncLive.

Liso-Cel Prolongs Responses, PFS, and OS in Pretreated, High-Risk, R/R CLL

March 6th 2025

Treatment with liso-cel induced long-term CR/CRi rates and high uMRD rates in patients with CLL/SLL following progression on BTK inhibition and venetoclax.